Inhibitory effect of famotidine on cat gastric secretion
Tóm tắt
The inhibitory effect of the novel H2 receptor antagonist famotidine was studied in conscious gastric fistula cats against dimaprit-induced hypersecretion, in comparison with ranitidine. On the secretory plateau induced by dimaprit (2 μmol kg−1 h−1) famotidine (0.05–0.2 μmol kg−1 i.v.) exerted a dose-dependent inhibitory effect, being approximately 4.5 times as potent as ranitidine (ID50 values were 0.067±0.015 and 0.30±0.025 μmol kg−1 for famotidine and ranitidine, respectively). No significant differences were found between the two drugs, as for the time-course of the inhibitory effect. Famotidine (0.01–0.32 μmol kg−1 h−1) caused a parallel displacement of the dose-response curve to dimaprit to the right, without reducing the maximum response to the stimulant, thus behaving as a competitive antagonist, like ranitidine. pA2 values for famotidine and ranitidine were 7.95 and 6.92, respectively. In the same range of doses famotidine dose-dependently reduced also the secretory response to histamine. From these data it was concluded that famotidine is a potent histamine H2 receptor antagonist in the cat gastric mucosa; moreover, conversely from “in vitro” data, the antagonism was surmountable even at the highest doses tested. In vivo experiment, therefore, did not reveal any particular feature of this compound, apart from the undoubtedly high potency, in comparison with other members of the family.
Tài liệu tham khảo
R. G. Pendleton, M. L. Torchiana, C. Chung, P. Cook, S. Wiese and B. V. Clineschmidt,Studies on MK-208 (YM-11170) a new slowly dissociable H2 receptor antagonist. Arch. int. Pharmacodyn.266, 4–16 (1983).
A. J. Shepherd-Rose and R. G. Pendleton,Studies on the H2-receptor antagonism of MK-208 in isolated rabbit gastric glands. Eur. J. Pharmacol.106, 423–426 (1984).
J. P. Buyniski, R. L. Cavanagh, A. W. Pircio, A. A. Algieri and R. R. Crenshaw, Structure-activity relationships among newer histamine H2-receptor antagonists, InHighlights in receptor chemistry, p. 195 (Eds. C. Melchiorre and M. Giannella). Elsevier, Amsterdam 1984.
J. W. Black, P. Leff and N. P. Shankley,Further analysis of anomalous pK B values for histamine H2-receptor antagonists on the mouse isolated stomach assay. Br. J. Pharmacol.86, 581–587 (1985).
G. Bertaccini, G. Coruzzi, E. Poli and M. Adami,Pharmacology of the novel H2 antagonist famotidine: in vitro studies. Agents and Actions19 (1986, in press).
M. Takeda, T. Takagi and H. Malno,H2 blocking and antisecretory activity of 3[[[[2-(diaminomethylene)amino]-4-thiazolyl]methyl]-thiol]-N-sulfamoylpropionamide (YM-11170) in anaesthetized dogs. Jap. J. Pharmac.31, Suppl. 222P (1981).
T. Takagi, M. Takeda and H. Malno,Effect of a new potent H2 blocker, 3[[[[2-(diaminomethylene) aminol]-4-thiazolyl]methyl]-thio]-N-sulfamoylpropionamide (YM-11170) on gastric secretion induced by histamine and food in conscious dog. Arch. int. Pharmacodyn. Ther.256, 49–58 (1982).
R. G. Pendleton, P. G. Cook, A. Shepherd-Rose and A. Mangel,Effects of H2-receptor antagonists upon physiological acid secretory states in animals. J. Pharmac. exp. Ther.233, 64–69 (1985).
G. Bertaccini and C. Scarpignato,Inhibition of gastric acid secretion in the cat by the histamine H2-receptor antagonists ranitidine and cimetidine. Ital. J. Gastroenterol.13, 248–252 (1981).
C. Scarpignato, M. G. Girone, and G. Bertaccini,Inhibitory effect of the new histamine H2-antagonist oxmetidine (SKF 92994) on dimaprit-induced gastric secretion. Ital. J. Gastroenterol.14, 16–19 (1982).
C. Scarpignato, R. Tramacere, M. Tangwa and G. Bertaccini,Effect of the new H2-receptor antagonist mifentidine on gastric acid secretion in the cat: comparison with cimetidine and ranitidine. Arch. int. Pharmacodyn. Ther.276, 142–151 (1985).
S. Emas, K. G. Swan, and E. D. Jacobson, Methods of studying gastric secretion. In:Handbook of Physiology, Section 6, vol. 2, Eds. C. F. Code, American Physiological Society, Washington DC, p. 743 (1967).
O. Arunlakshana and H. O. Schild,Some quantitative uses of drug antagonism. Br. J. Pharmacol.14, 48–58 (1959).
R. J. Tallarida, A. Cowan and M. W. Adler,pA 2 and receptor differentiation: a statistical analysis of competitive antagonism. Life Sci.25, 637–654 (1979).
R. W. McCallum, B. Kuljian, A. N. Chremos, M. A. Tupy Visich and P. B. Huber,Prolonged gastric antisecretory effect of a novel H2-receptor inhibitor, MK-208. Gastroenterology84, 1245 (1983).
P. Müller, H. G. Dammann, H. Schmidt-Gayk, K. Lichtwald, C. Staiger and B. Simon,Famotidine (MK-208): duration of action, 24-hour intragastric acidity, antipyrine kinetics and basal hormone levels in man. Gastroenterology86, 1190 (1984).
J. Lacey Smith,Clinical pharmacology of famotidine. Digestion32, 15–23 (1985).
K. Ohe, M. Kohchi, H. Matsumoto and M. Inoue,Specificity of H2-receptor antagonists, cimetidine, ranitidine, famotidine and TZU-0460, for histamine-stimulated acid secretion in vitro. XII Int. Congr. Gastroenterol., Lisbon, Sept. 8–12, p. 851 (1984).
G. Bertaccini and C. Scarpignato,Histamine H2-antagonists modify gastric emptying in the rat. Br. J. Pharmac.77, 443–448 (1982).
G. Bertaccini and G. Coruzz,Interaction between histamine H2-receptor antagonists and the cholinergic system. Drug Therapy, Special Suppl. 9–19 (1984).
G. Bertaccini and G. Coruzzi,Histamine H2-receptor agonists and antagonists on pancreatic exocrine secretion of the dog. Agents and Actions16, 211–214 (1985).
U. Klotz, P. Arvela and B. Rosenkranz,Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide. Eur. J. Cl. Pharmac.28, 671–675 (1985).
B. Simon, H. G. Dammann, G. Jakob, S. E. Miederer, P. Mueller, R. Ottenjann, F. Paul, T. Scholten, E. Schutz, E. Seifert and O. Stadelmann,Famotidine versus ranitidine for the short-term treatment of duodenal ulcer. Digestion32, Suppl. 1, 32–37 (1985).